Welcome to our dedicated page for ARVINAS SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARVINAS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARVINAS's regulatory disclosures and financial reporting.
Form 4 filed for Arvinas, Inc. (ARVN) discloses that Chief Financial Officer Andrew Saik executed a Rule S sale of 5,700 common shares on 24 June 2025 at a price of $7.61 per share. The transaction was automatic and solely to cover tax-withholding obligations related to the vesting of 25 % of restricted stock units granted on 24 June 2024. Following the sale, Saik retains beneficial ownership of 164,401 shares, held directly. No derivative transactions were reported. The filing reflects a routine administrative sale rather than an open-market disposition, and it does not alter Saik’s officer status or ownership structure.
Arvinas, Inc. (NASDAQ: ARVN) — Form 144 filed for proposed insider sale
The notice, dated 24 June 2025, discloses an intent to sell up to 5,927 shares of Arvinas common stock through broker Morgan Stanley Smith Barney LLC. At an aggregate market value of US$43,593 and with 72,991,390 shares outstanding, the sale represents roughly 0.008 % of the company’s equity float.
The securities were acquired the same day via the vesting of restricted stock units issued by Arvinas, with no cash consideration. The filer reports no other sales in the previous three months and signs the customary representation that no undisclosed material adverse information is known.
Form 144 is a notice only; it does not obligate execution of the transaction. Given the small size relative to total shares outstanding and the lack of additional material disclosures, the filing appears routine and is unlikely to have a meaningful impact on Arvinas’ capital structure, operations, or near-term share price dynamics.
Arvinas, Inc. (ARVN) – Form 4 insider transaction filed 06/18/2025
Chief Scientific Officer Angela M. Cacace disclosed the sale of 2,583 common shares on 06/17/2025 at $7.49 per share. The company executed this sale automatically to satisfy tax-withholding obligations arising from the vesting and settlement of 50% of restricted stock units (RSUs) granted on 06/17/2024.
Post-transaction, the executive retains 154,248 shares held directly. No new options, warrants, or other derivative securities were reported, and the filing does not reference a Rule 10b5-1 trading plan.
Because the sale was issuer-directed and linked to tax withholding rather than discretionary portfolio rebalancing, it carries limited signaling value regarding the executive’s outlook. The relatively small size (≈1.7% of her holdings) further supports a neutral interpretation for investors.